TribeMD US ads

SnackableHealth| From Intervention to Prevention How can cardiology move beyond stents and catheters? In this episode, Dr. Deepak Bhatt (Mount Sinai Fuster Heart Hospital) and Dr. Bhavik Modi (Glenfield Hospital, UK) discuss how secondary prevention clinics after acute coronary syndromes are transforming post-ACS care — improving long-term outcomes through structured, multidisciplinary follow-up. Watch the full conversation on TribeMD and see how prevention is redefining the future of cardiology - https://4soci.al/t4wozu

SnackableHealth on TribeMD: The HELIOS-B trial brings breakthrough results for ATTR cardiomyopathy. Dr. Scott Solomon (Harvard) and Dr. Marianna Fontana (UCL) discuss how vutrisiran met all endpoints—improving survival, reducing CV events, and enhancing quality of life—with just four injections per year. Watch the full discussion on TribeMD - https://4soci.al/t4woai

How can changes in cardiac structure and function help us better understand ATTR-CM? In this episode, Dr. Scott Solomon and Dr. Karola Jering discuss echocardiographic findings from the HELIOS-B trial, including changes in cardiac structure and function over time and their relationship with clinical outcomes. The conversation offers important insights into the progression of ATTR-CM and the role of cardiac function in understanding patient outcomes.

Gene silencers can dramatically lower circulating transthyretin. But is it safe to suppress an endogenous protein for years? Dr. Scott Solomon and Prof. Julian Gillmore discuss the safety profile of vutrisiran in patients with ATTR-CM, drawing on findings from the HELIOS-B trial and clinical experience. The conversation covers thyroid function, vitamin A transport and supplementation, injection-site tolerability, and other safety considerations associated with TTR reduction. Watch the full discussion: https://lnkd.in/dU3WQgGJ

🫀 How do therapies for ATTR-CM target the underlying disease mechanism? In this video, Dr. Scott Solomon and Prof. Marianna Fontana discuss the pathophysiology of transthyretin amyloid cardiomyopathy (ATTR-CM) and explain how different therapeutic approaches interfere with disease progression. Throughout the conversation, they cover: ✔️ The role of transthyretin (TTR) in the development of ATTR-CM; ✔️ The differences between TTR stabilizers and gene silencers; ✔️ How each strategy reduces new amyloid deposition; ✔️ What we know—and what we still need to learn—about monitoring TTR levels during treatment. A practical, evidence-based discussion to better understand the mechanisms that guide the management of ATTR-CM. ▶️ Watch the full video on the site: https://bit.ly/4hi7RXR

A deeper understanding of ATTR-CM begins with understanding its pathophysiology. Explore expert perspectives from Dr. Scott Solomon and Prof. Marianna Fontana as they discuss the mechanisms underlying transthyretin amyloid cardiomyopathy and the biological processes that drive disease progression. Begin with a brief knowledge check, then access the full expert discussion to deepen your understanding of ATTR-CM. 🫀 Because every meaningful advance in patient care starts with a deeper understanding of the science. 🔗 Watch the video: https://bit.ly/4oVNUIa